Scarica l'app Stockscreener
49.62
40.45%
14.29
Pre-mercato:
49.00
-0.62
-1.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.33
Aprire:
$44.91
Volume 24 ore:
13.12M
Relative Volume:
7.99
Capitalizzazione di mercato:
$5.94B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-9.4335
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+29.93%
1M Prestazione:
+35.24%
6M Prestazione:
+7.87%
1 anno Prestazione:
-13.07%
Intervallo 1D:
$44.91
$50.22
Intervallo di 1 settimana:
$35.22
$50.22
Portata 52W:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
49.62 | 4.23B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics Incorporated stock prediction for this weekPortfolio Growth Summary & Weekly Chart Analysis and Trade Guides - Newser
Predicting Cytokinetics Incorporated trend using moving averagesGDP Growth & Safe Entry Trade Reports - Newser
Can Cytokinetics Incorporated recover in the next quarterMarket Rally & Free Safe Capital Growth Stock Tips - Newser
Applying chart zones and confluence areas to Cytokinetics Incorporated2025 Year in Review & Growth Oriented Trade Recommendations - Newser
Technical signs of recovery in Cytokinetics IncorporatedMarket Sentiment Summary & Safe Entry Zone Tips - Newser
How high can Cytokinetics Incorporated stock goJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Real time social sentiment graph for Cytokinetics IncorporatedTrade Risk Report & Low Drawdown Trading Techniques - Newser
Detecting support and resistance levels for Cytokinetics IncorporatedChart Signals & High Win Rate Trade Alerts - Newser
Cytokinetics’ Aficamten with breakthrough Phase III results - European Biotechnology Magazine
Cytokinetics Shares Jump 40.45% on Aficamten HCM Data $630M Volume Ranks 162nd - AInvest
Is Cytokinetics Incorporated on track to beat earnings2025 Key Highlights & Smart Swing Trading Techniques - خودرو بانک
Should I buy Cytokinetics Incorporated stock nowIPO Watch & Daily Profit Maximizing Trade Tips - خودرو بانک
Cytokinetics’ Aficamten Shows Head-To-Head Advantage Vs. Beta Blockers - insights.citeline.com
How to read the order book for Cytokinetics IncorporatedEarnings Recap Report & Weekly Top Gainers Alerts - Newser
Cytokinetics at Citi’s Biopharma Conference: Aficamten’s Promising Path - Investing.com
Aficamten Bests Metoprolol in Cytokinetics' Trial for Obstructive Hypertrophic Cardiomyopathy - PharmTech
Bitcoin gains, Frontier upgraded, Cytokinetics trial results - Yahoo Finance
Cytokinetics Skyrockets On 'Provocative' Results In Heart Disease - Investor's Business Daily
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics’ Aficamten: Navigating Regulatory Hurdles and Market Potential in the OHCM Space - AInvest
Cytokinetics Appoints New Director Amid Revenue Boost and Strategic Moves - StocksToTrade
Board Appointment Boosts Cytokinetics’ Growth Projections - timothysykes.com
Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever - Barron's
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? - Benzinga
Cytokinetics makes its case for heart-failure drug ahead of FDA decision, stock surges more than 40% - The Business Journals
Cytokinetics says heart disease drug more effective than standard-of-care, shares jump - TradingView
Cytokinetics shares surge 35.66% in premarket after positive results from MAPLE-HCM III trial. - AInvest
Cytokinetics Soars 35.13% on Promising Heart Disease Data - AInvest
Is Cytokinetics Incorporated’s ROE strong enough2025 Major Catalysts & Advanced Swing Trade Entry Plans - خودرو بانک
Fed Watch: Is Cytokinetics Incorporated a top pick in the sectorCEO Change & Safe Investment Capital Preservation Plans - خودرو بانک
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough - Stocktwits
Is Cytokinetics Incorporated forming a reversal patternJuly 2025 Review & Safe Capital Investment Plans - Newser
Pattern recognition hints at Cytokinetics Incorporated upside2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Multi asset correlation models including Cytokinetics IncorporatedQuarterly Trade Summary & Step-by-Step Trade Execution Guides - Newser
Risk adjusted return profile for Cytokinetics Incorporated analyzedMarket Growth Summary & Technical Pattern Based Signals - Newser
Published on: 2025-09-01 20:47:13 - خودرو بانک
Cytokinetics Incorporated stock retracement – recovery analysis2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
What’s next for Cytokinetics Incorporated stock priceMarket Growth Review & Consistent Profit Focused Trading Strategies - Newser
Will Cytokinetics Incorporated benefit from macro trendsMarket Rally & Risk Managed Investment Strategies - Newser
Custom Dashboard Highlights Cytokinetics Incorporated Price MomentumJuly 2025 Spike Watch & Low Drawdown Investment Strategies - beatles.ru
Cytokinetics’ aficamten bests beta blocker in head-to-head trial - The Pharma Letter
Cytokinetics Incorporated stock volume spike explainedQuarterly Trade Summary & Weekly Sector Rotation Insights - Newser
What the charts say about Cytokinetics Incorporated todayWeekly Trade Summary & Community Consensus Trade Signals - Newser
Does Cytokinetics Incorporated show high probability of reboundLayoff News & AI Based Buy and Sell Signals - Newser
How to build a custom watchlist for Cytokinetics IncorporatedMarket Activity Summary & Daily Technical Stock Forecast Reports - Newser
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 - markets.businessinsider.com
Cytokinetics Incorporated stock chart pattern explainedMarket Performance Recap & Real-Time Volume Surge Alerts - Newser
Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial - Stock Titan
What data driven models say about Cytokinetics Incorporated’s future2025 Top Gainers & Capital Efficient Trade Techniques - Newser
Cytokinetics Incorporated Crosses 200 Day MA — Signal or NoiseMarket Sentiment Review & Real-Time Buy Zone Alerts - beatles.ru
Understanding Cytokinetics Incorporated’s price movementEarnings Overview Report & Consistent Return Strategy Ideas - Newser
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):